NEWS & EVENTS

Latest news and upcoming events

Memo Therapeutics increases Series C financing to CHF 45 million
07 May 2024

Memo Therapeutics increases Series C financing to CHF 45 million

Upcoming events

  • Bio€quity Europe
    14 - 16 May 2024,
    San Sebastián

    download

  • AseBio Investor Day 2024
    15 May 2024,
    San Sebastián

    download

  • ESMO Congress 2024
    13 - 19 September 2024,
    Barcelona

    download
Xeltis initiates first-ever pivotal trial of a synthetic restorative pulmonary heart valve<
08 Jul 2021

Xeltis initiates first-ever pivotal trial of a synthetic restorative pulmonary heart valve

Patient’s own tissue naturally turn device into living heart valves and may reduce need for re-interventions
Adcendo Appoints Michael Pehl as Chief Executive Officer<
07 Jul 2021

Adcendo Appoints Michael Pehl as Chief Executive Officer

Experienced Industry Leader with successful Oncology, Immunotherapy & ADC Development Track Record
AM-Pharma Appoints Mark Altmeyer as Chairman of its Supervisory Board<
06 Jul 2021

AM-Pharma Appoints Mark Altmeyer as Chairman of its Supervisory Board

Mr. Altmeyer will provide important guidance as the Company expands its global clinical development program.
Ysios Capital’s portfolio company CVRx Inc. prices IPO on NASDAQ<
05 Jul 2021

Ysios Capital’s portfolio company CVRx Inc. prices IPO on NASDAQ

This is a major achievement for Ysios as CVRx is its fifth portfolio company to be listed on NASDAQ, and the second within just three months.
AM-Pharma Enrolls First Patient in Japan for Ongoing Phase III SA-AKI Pivotal REVIVAL Trial<
01 Jul 2021

AM-Pharma Enrolls First Patient in Japan for Ongoing Phase III SA-AKI Pivotal REVIVAL Trial

REVIVAL study is evaluating ilofotase alfa, the Company’s proprietary recombinant human alkaline phosphatase, for the treatment of sepsis-associated acute kidney injury (SA-AKI).
Aura Biosciences Assembles New Bladder Cancer Focused Scientific Advisory Board<
18 Jun 2021

Aura Biosciences Assembles New Bladder Cancer Focused Scientific Advisory Board

The new SAB will be comprised of seven members and will work closely with Aura’s senior management.
AM-Pharma Appoints Martijn Negen as VP Commercial Strategy<
16 Jun 2021

AM-Pharma Appoints Martijn Negen as VP Commercial Strategy

Martijn Negen has over 20 years of experience in pharmaceutical, biotech and diagnostic companies.
VarmX appoints Dr. Jan Öhrström as CEO, and Dr. Alex Gold to Supervisory Board<
15 Jun 2021

VarmX appoints Dr. Jan Öhrström as CEO, and Dr. Alex Gold to Supervisory Board

VarmX today announces the appointment of Dr. Gerard Short, MBBS, as Chief Medical Officer (CMO).
CorWave Successfully Performed a 90-Day In Vivo Study on Its Revolutionary Cardiac Pump Synchronized With the Native Heart, Results Presented at ASAIO Meeting<
14 Jun 2021

CorWave Successfully Performed a 90-Day In Vivo Study on Its Revolutionary Cardiac Pump Synchronized With the Native Heart, Results Presented at ASAIO Meeting

These data confirmed the ability of the CorWave pump to provide chronic circulatory support with exceptional hemocompatibility.
CorWave Successfully Performed a 90-Day In Vivo Study on Its Revolutionary Cardiac Pump Synchronized With the Native Heart, Results Presented at ASAIO Meeting<
14 Jun 2021

CorWave Successfully Performed a 90-Day In Vivo Study on Its Revolutionary Cardiac Pump Synchronized With the Native Heart, Results Presented at ASAIO Meeting

The results of the 90-day in vivo study were reported during an oral presentation entitled "Design Optimization of the CorWave Membrane LVAD."

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.

Bitplex 360 Кракен даркнет кракен даркнет Blacksprut Blacksprut Кракен ссылка кракен ссылка